Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib

Main Article Content

Brett King
Yale School of Medicine, Connecticut, USA

Jerry Shapiro
New York University Langone Health, New York, USA

Manabu Ohyama
Department of Dermatology, Kyorin University Faculty of Medicine, Tokyo, Japan

Alexander Egeberg
Bispebjerg Hospital, Copenhagen, Denmark

Yves Dutronc
Eli Lilly and Company, Indianapolis, USA

Yun-Fei Chen
Eli Lilly and Company, Indianapolis, USA

Wen-Shuo Wu
Eli Lilly and Company, Indianapolis, USA

Yuxin Ding
Eli Lilly and Company, Indianapolis, USA

Najwa Somani
Eli Lilly and Company, Indianapolis, USA

Rodney Sinclair
University of Melbourne, Melbourne, Australia

Keywords

Alopecia Areata, Baricitinib, Phase 3 trials, trajectories

References

1. Pratt C, et al. Nat Rev Dis Primers. 2017;3:17011

2. King B, et al. N Engl J Med 2022; 386:1687-1699.

3. King B, et al. J Am Acad Dermatol. 2021;85:847-853.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.184

Article Details

How to Cite
King, B. ., Shapiro, J. ., Ohyama, M. ., Egeberg, A. ., Dutronc, Y. ., Chen, Y.-F. ., Wu, W.-S. ., Ding, Y. ., Somani, N. ., & Sinclair, R. . (2023). Trajectories For Scalp Hair Regrowth In Patients With Severe Alopecia Areata Treated With Baricitinib. SKIN The Journal of Cutaneous Medicine, 7(2), s184. https://doi.org/10.25251/skin.7.supp.184
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Alopecia
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 > >>